Status:
COMPLETED
Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Migraine Disorders
Heart Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of telcagepant in the treatment of acute migraine in participants with stable vascular disease. Acetaminophen/paracetamol (APAP) will b...
Eligibility Criteria
Inclusion
- Stable coronary artery disease for 3 months or more
- 18 years of age or older with a history of migraine with or without aura
- Must use acceptable contraception throughout the study
Exclusion
- Pregnant, breast-feeding, or planning to become pregnant during this study
- 50 years of age or older when migraines began
- Other pain syndromes that might interfere with study assessments, uncontrolled psychiatric conditions, dementia, or significant neurological disorders (other than migraine)
- History of gastric, or small intestinal surgery, or has a disease that causes malabsorption
Key Trial Info
Start Date :
March 17 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 2 2009
Estimated Enrollment :
165 Patients enrolled
Trial Details
Trial ID
NCT00662818
Start Date
March 17 2008
End Date
September 2 2009
Last Update
October 19 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.